Stratasys’3D printed RadioMatrix technology is now fully available in the US, offering clinicians a platform to create ...
Stratasys has announced full commercial availability of its RadioMatrix radiopaque 3D printing material in the United States.
Stockhead on MSN
Singular Health seeks FDA 510(k) clearance for next-generation 3D medical-imaging and sharing platform
Singular Health has submitted a 510(k) premarket notification to the US Food and Drug Administration (FDA) for its ...
News Medical on MSN
New technique overcomes technological barrier in 3D brain imaging
Scientists at the Swiss Light Source SLS have succeeded in mapping a piece of brain tissue in 3D at unprecedented resolution using X-rays, non-destructively. The breakthrough overcomes a long-standing ...
Vincent Reid, MD, FACS, Chairman of Surgery and Medical Director at the Hall Perrine Cancer Center, Mercy Cedar Rapids, to share clinical experience and real-world case studies using TumorSight (TM) ...
A recent review explored the evolution of visual arts in cardiovascular medicine over time, the understanding, diagnosis, and ...
Companies in November announced new efforts to fine-tune foundational models to advance radiology intelligence and implement ...
The MARS scanner will be installed at the Centre for Advanced Preclinical Imaging (CAPI) within the First Faculty of Medicine ...
SimBioSys®, an AI-driven precision medicine company revolutionizing how cancer is understood and treated, and Ricoh 3D for Healthcare, LLC, a wholly owned subsidiary of Ricoh USA, Inc. focused on ...
NVIDIA technology is now integrated into several of GE HealthCare’s new imaging solutions, including Photonova Spectra1, SIGNA Sprint with Freelium2, SIGNA Bolt3, Vivid Pioneer, and Pristina Recon DL.
Ranchi's medical landscape is about to transform as the Rajendra Institute of Medical Sciences (Rims) prepares to roll out state-of-the-art MRI servic ...
Medical Device Network on MSN
GE HealthCare secures PMA for deep-learning 3D mammography system
GE HealthCare’s Pristina Recon DL tool has received pre-market authorisation (PMA) from the US Food and Drug Administration (FDA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results